Register Now
Login to Partnering
Youtube Linkedin Facebook

Testimonials from our exhibitors​

Get a taste of what DxPx has in store for you, through the eyes of our past exhibitors!

sponsor lino biotech

Life Science Tools

Label-free biosensoring directly from crude samples

lino Biotech is the world´s only provider of Focal Molography – an entirely new method for measuring molecular interactions in living cells or crude biological samples. The broadly patented technology offers label-free detection assays while eliminating signal disturbances due to temperature changes or non-specific binding.

Dr. Mirko Stange
Mirko Stange, CEO

1. What is it you are looking for when going to partnering conferences?

  • Meeting new investors, potential new clients, or multipliers
  • Promoting my own startup
  • Follow-up meetings or face-to-face
dxpx eu startup citz ticket shop

2. What is your company all about?

lino Biotech was incorporated in Zürich, Switzerland, in March 2020 after 10 years of research as spin-out from Roche Diagnostics. We have developed a reagent-free method for measuring molecular interactions in living cells or crude biological samples called focal Molography. With our first products, we aim to lower the cost of drug discovery and cell and gene therapies and make them more cost effective and accessible for a broader patient population by offering access to a unique analytical technology to optimize production processes at highest quality level. Our team consists of highly qualified experts with different backgrounds in Biochemistry, Biophysics, Biomedical Engineering, Software Engineering and Business Development, all with the same goal.

3. Why did you found your company?

We can detect multiple target-types simultaneously – without purification – to make analytics faster and more cost-effective. Our sensing principle is based on light interference caused by an imprinted molecular grating in chip. Cell and gene therapies generally face the issue of a long product quality control with high production cost. That´s why our biosensors therefore enable much faster and more accurate characterization of cell therapy products while at the same time helping the manufacturer to substantially reduce production cost. We started with a founder team of three people covering business and scientific aspects with great support of ETH Zurich and Roche Basel, then expanded our team.
lino

4. Waht is your current fundraising strategy?

We can detect multiple target-types simultaneously – without purification – to make analytics faster and more cost-effective. Our sensing principle is based on light interference caused by an imprinted molecular grating in chip. Cell and gene therapies generally face the issue of a long product quality control with high production cost. That´s why our biosensors therefore enable much faster and more accurate characterization of cell therapy products while at the same time helping the manufacturer to substantially reduce production cost. We started with a founder team of three people covering business and scientific aspects with great support of ETH Zurich and Roche Basel, then expanded our team.

5. What were your biggest lessons learned and biggest accomplishments?

One of the biggest accomplishments was definitely establishing a great team around our trend-setting technology, we also solved multiple open questions regarding a scalable production of our sensor consumables and designed our first industrial instrument. Challenges arising from the COVID pandemic and other ongoing crises, stopped or slowed us down in regards of closing our Series A and with suppliers for our materials.

6. Have you attended DxPx previously?

We (so far) had attended DxPx EU and US in 2021, and the DxPx US Conference this year, and are very convinced of the whole concept!
Having partnering cubicles simplifies meeting investors and clients in a quieter atmosphere than is otherwise the case at conferences and the whole networking tool is much more convenient and it is impressive how many VC are present.

Returning to Düsseldorf, Germany – 15-16 November 2022 for 2-days onsite event of effective networking opportunities. Join DxPx EU to discuss M&A, licensing and financing opportunities, meet old acquaintances and make new international contacts.

Meet investors and industry partners who share your love for Diagnostics, Digital Health, Precision Medicine & Life Science Tools. 

  • 500+ participants with 100+ VC, corporate VC and other investors expected: All sharing your interest in life science outside therapeutics and biotech
  • 40 exhibitors: Selected innovations featured at our innovation pavilion
  • 12 Panels: Featuring industry experts and investors sharing their knowledge
  • 1 Pitch award: 8 companies that are carefully selected by over 30 VCs prior to the event will present their business and compete for funding of up to 2 Mio US
… and our famous rooftop reception on day 2 of the event.

“The cooperation of AACC as largest diagnostics trade fair in the world with the DxPx is a clear win for us. We look forward to participating again as partner and juror for the 42plus1 Pitch Award.”

qiagen logo sponsordxpx eu conference
Sebastian Swienty

Sebastian Swienty

Senior Director

“Thanks for this great event. I truly enjoyed it. The format facilitated deep and very efficient interactions with potential partners.”

sponsor roche
Dr. Babette Güldenpfennig

Dr. Babette Güldenpfennig

Head of Global Licensing

Don't miss our investor conferences & early-stage investing events:

dxpx us adlm logos
DxPx US

DxPx Industry & Investor Conference US:
4 Days In-Person

July 29 - Aug. 1, 2024
Chicago, IL
In the ADLM

Stay up to date and sign up for our latest news:

Next: DxPx U.S. 2025
  • 3 Days In-Person
  • July 29 - 31, 2025
  • McCormick Place
    Convention Center
    Chicago, Illinois, USA
Next: DxPx EU 2026
  • 2 Days In-Person
  • Reception: February 5, 2026
    Partnering Day & 42PLUS1:
    February 6, 2026
  • Munich, Germany
Download Brochure
DxPx media
Useful links

© Copyright DxPx 2025. All Rights Reserved.

Youtube Linkedin Facebook

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.

Experience

Christoph Brandenberger

Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.

Experience

John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.

Experience

Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.

Experience

FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Experience